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Abstract
Background: In order to evaluate the newly implemented gender-neutral HPV vaccination program, knowledge on
the pre-vaccine prevalence of HPV infection is of paramount importance. Data on HPV infection among the women
with no known previous cytological abnormalities are inexistent in Austria. This study presents data on the prevalence
and distribution of HPV genotypes among women with no known cytological abnormalities in west Austria.
Methods: Women between 18 and 65 years of age attending annual cervical cancer screening examinations were
included in the study. Data on socio-demographic and reproductive factors were collected using structured
questionnaires. Corresponding cervical swab samples were tested for the presence of HPV DNA and were genotyped.
Questionnaire data and HPV status were linked with the corresponding cytological findings.
Results: A total of 542 women were included in the study. The mean age of the study participants was 35.9 (SD = 11.
5). The prevalence of HPV infection was 20.5 %. HPV 16 (6.5 %), HPV 33 (3.3 %) and HPV 31 (3.0 %) were the dominant
genotypes detected. Multivariate analysis showed that women younger than 30 years of age, smokers, women with a
higher number of lifetime sexual partners and those living in the eastern districts of the study region were at
significantly higher risk of HPV infection.
Conclusions: With this study we present the first data on the prevalence of cervical HPV genotypes among a
screening population in Austria. The results not only fill the missing information on HPV infection in this group
of women in the country, they also provide baseline data for a future evaluation of the impact of the Austrian
gender-neutral HPV immunization program. Moreover, our finding of higher HPV prevalence in the eastern
compared to the western district of the study region may – at least partly – explain the east–west gradient in
the standardized incidence rate of cervical cancer in the region.
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Background
Genital human papillomavirus (HPV) infection is the most
common sexually transmitted viral infection [1]. It is
mostly transient resulting in no cervical lesions or leading
to low-grade lesions that often regress spontaneously.
However, a non-negligible proportion of the infections
persists and results in subsequent pre-cancerous and can-
cerous lesions [2, 3].
For the prevention of cervical and other genital neopla-
sia, three vaccines – Gardasil® (quadrivalent vaccine
against HPV types 6, 11, 16 and 18), Gardasil 9® (nonava-
lent vaccine against HPV types 6, 11, 16, 18, 31, 33, 45, 52
and 58) and Cervarix® (bivalent vaccine against HPV types
16 and 18) – have been approved for use [4–7]. Developed
nations like Australia and several countries in Europe and
North America have integrated HPV immunisation in
their vaccination programs soon after the approval. Ac-
cordingly, in these countries significant reductions have
been observed in many high-risk HPV (hrHPV) infec-
tions as well as in HPV-associated warts and pre-
cancerous lesion [8–10].
In Austria these vaccines have been recommended and
available for use since their approval [11, 12]. However, it
is only since the beginning of 2014 that the country inte-
grated HPV vaccine in the free of charge immunization
program [12]. Starting from the autumn of 2014, 4th
grade elementary school girls and boys receive two
doses of Gardasil (0–6 months) as part of school-based
immunization program. In order to assess the long-
term impact of this program, pre-vaccine data on the
prevalence of HPV infection and genotype distribution
are of paramount importance [11].
Data on the prevalence of HPV infection is scarce in
Austria. Until the end of 2013 the only data available
were those on HPV prevalence in cervical cancer sam-
ples [13, 14]. L Rössler et al. recently published data on
the prevalence of HPV among Austrian women with
high- grade intraepithelial lesions [15]. However, to date,
there are no data on the epidemiology of HPV infection
among women without any known cytological abnor-
malities (Additional file 1: Figure S1). One of the early
parameters in evaluating the success of HPV immunisa-
tion programs is the comparison of HPV prevalence in
the pre- and post-HPV-vaccine era.
The main aim of this study is to present data on the dis-
tribution of HPV genotypes among screening population
of women in west Austria. With this study, we also aim to
address the role of HPV infection in an interesting differ-
ence in the cervical cancer incidence observed between
eastern (standardized incidence rate (SIR) in the range of
1.2 to 1.5) and western (SIR in the range of 0.6 to 0.9) dis-
tricts of the study region [16]. To our knowledge this is
the first report on the epidemiology of cervical HPV infec-
tion among screening population of women in Austria.
Methods
Study population
The study population included sexually active women aged
18–65 years undergoing routine gynaecological screening
at five randomly selected gynaecological clinics in west
Austria (Tyrol) between March 2013 and February 2015.
Screening for cervical cancer in Austria is opportunistic in
nature but is provided free-of-charge at a yearly basis.
Women who have consented to participate in the study
filled out questionnaires on socio-demographic, reproduct-
ive and sexual characteristics. The questionnaires were
then sent back to our institute (Division of Virology of the
Medical University of Innsbruck) with the corresponding
cervical samples.
For the ascertainment of persistent HPV infection,
those women who tested positive for one or more of the
known hrHPV types were invited for a follow up HPV
testing approximately a year after the baseline.
The samples
One of the two swabs taken from the patient was sent to
our institute, the other one was sent to a pathology labora-
tory (Dr. P. O.) for cytological (PAP) examination. Cervical
swabs were taken with Abbott Cervi-Collect specimen
collection kit. DNA extraction (Biomerieux EasyMag 2.0)
took place within 2 days of arrival of samples at our insti-
tute. The extracted DNA samples were stored at −20 °C
until HPV testing.
Detection and Genotyping of HPV
For the detection and genotyping of HPV, we used a two-
step testing procedure. The first test is a real-time PCR
that identifies the presence or absence of HPV DNA
(HPV RealQuality, AB Analitica, Padova, Italy). The sec-
ond step involves genotyping of all positive samples using
a reverse line blot hybridization system (AmpliQuality
HPV-TYPE EXPRESS, AB Analitica, Padova, Italy). This
genotyping kit was able to identify 40 different HPV types,
including all high-risk, probable high-risk and low-risk
types. Membrane stripes coated with genotype specific
DNA probes are used to identify the different geno-
types through hybridization of denatured PCR product.
Multiple infections were easily detected. The analysis
includes dUTP/UNG system for the prevention of con-
tamination due to carry-over.
Cytology
Cytological examinations were interpreted according to
Munich Nomenclature for the Cytological Diagnosis of
Cervical Pap smears [17]. In our study cytological find-
ings were classified as abnormal (PAP III+) if the path-
ologist reported PAP III (unclear finding corresponding
in the Bethesda classification system to ASCUS), PAP
IIID (cells of mild or moderate dysplasia corresponding
Borena et al. BMC Public Health  (2016) 16:889 Page 2 of 8
in the Bethesda classification system to LSIL or HSIL re-
spectively), PAP IVA (cells of severe dysplasia or carcin-
oma in situ corresponding in the Bethesda classification
system to HSIL or AIS, respectively), PAP IVB (cells of
invasive carcinoma not safely excluded, corresponding in
the Bethesda classification system to HSIL or AIS with
features suspicious for invasion, respectively) or PAP V
(cells of invasive cervical carcinoma).
Data analysis
HPV prevalence was computed in crude and age stan-
dardized manner. Chi square or Fischer’s exact test
(two-tailed) were used for analysis of distribution of sev-
eral hrHPV genotypes. Logistic regression model was
used to compute odds ratios for HPV positivity across
several variables including smoking status, educational
level, marital status, number of life time sexual partners
and age at first sexual contact with corresponding 95 %
confidence intervals. P-values <0.05 were considered
significant. Prevalence ratio of HPV infection was also
computed across Tyrolean districts.
Statistical analyses were performed in SPSS (Version
20.0. Armonk, NY: IBM Corp.).
Results
Baseline characteristics
Baseline characteristics of the study participants are pre-
sented in Table 1. A total of 542 women were included in
this study. The mean age of the study participants was
35.9 (SD = 11.5) years. One third of the women were
current smokers and 27 % were overweight. Mean age at
first sexual contact was 16.8 years (SD = 2.2). A quarter of
the study participants reported to have had more than five
life-time sexual partners. Two hundred thirteen (39.3 %)
participants in this study were from eastern Tyrolean dis-
tricts (Kufstein, Kitzbühel) whereas 205 (37.8 %) represent
two western districts (Imst and Landeck). Just over a fifth
of the participants were from the city of Innsbruck (IBK)
or its suburbs (IL). Additional file 2: Figure S2 presents a
map of the studied region.
HPV immunization
Immunisation coverage among the studied population
was very low (3.7 %). The attitude of the study partici-
pants towards HPV vaccine is presented in Table 1. Not
knowing about the vaccine and/or not being informed
about it was the most frequent reason given by the
study participants for not being vaccinated. When
asked if they would get vaccinated provided the vaccine
was available for free, the majority of the study partici-
pants showed undecidedness and a minority (13 %) de-
clined clearly.
HPV prevalence
Figure 1 shows the distribution of all detected genotypes
among HPV positive women. A total of 111 (20.5 %)
participants were positive for one or more of HPV geno-
types. Among the high risk types HPV 16 is the most
commonly detected genotype followed by HPV 33 and
HPV 31. Out of the low risk genotypes HPV 53 and
HPV 54 are the most commonly detected types followed
by HPVs 82 and 90. Only three participants (2.7 % of
HPV positive participants) were positive for HPV 6 and
none had HPV 11.
Table 1 Baseline characteristics of study participants
Total (n = 542)
Age, years
Mean (SD) 35.9 (11.5)
Median 34.5




IL and others 55 (10.1)
BMI, kg/m2
Mean (SD) 23.4 (4.0)
Smoking status, n (%)
Current smoker 175 (32.3)
Non-smokers 364 (67.1)
Life time sexual Partners, n (%)
≤ 5 340 (62.7)
6–10 95 (17.5)
≥ 11 41 (7.6)
HPV vaccinated, n (%)
At least one vaccine 20 (3.7)
Reasons for not being vaccinated, n (%)
Did not know 201 (37.1)
Expensive 42 (7.8)
Fear of side effect 78 (14.4)
Other reasons 155 (28.6)
No response 86 (15.9)
If vaccine available for free, n (%)
Will get vaccinated 179 (33)
Will not get vaccinated 72 (13.3)
Do not know 233 (43)
No response 58 (10.7)
SD standard deviation, BMI body mass index
Oberland western districts (Imst, Landeck)
Unterland Eastern districts (Kufstein, Kitzbuehel), IBK Innsbruck, IL suburbs
of Innsbruck
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Fifty women (45.5 %) had HPV infection with multiple
genotypes whereas the slight majority presented with
single-genotype infections (Additional file 3: Figure S3).
The majority of the participants (91.8 %) are positive for
one of the genotypes classified as definitive, probable or
possible carcinogenic HPV types (IARC classification)
(Additional file 4: Figure S4) whereas only nine of HPV
positive participants (8.2 %) had infections with only
low risk genotypes [18]. A total of 73 women (65.7 %
of HPV positive women) are positive for one or more
of the high-risk genotypes that are covered in the
nonavalent HPV vaccine (HPV-types 16, 18, 31, 33,
45, 52 and 58).
Table 2 characterises the prevalence of any HPV and
selected high-risk types by socio-domographic and be-
havioural data. HPV infection was significantly higher
among individuals younger than 30 years of age. Smok-
ing, being single and/or divorced, having several life-
time sexual partners and starting sexual contact at a
younger age were significantly associated with higher
cervical HPV DNA detection rate. On the contrary
higher body mass index (BMI) was not associated with
increased risk of HPV infection showing rather a pro-
tective effect with a borderline statistical significance.
Analysis across Tyrolean districts showed that HPV
prevalence was higher among women from the eastern
districts compared to those from the west. The signi-
ficant association disappeared when analysis was ad-
justed for age, indicating that the observed difference
may be due to differences in the age distribution of the
study participants in these two regions. A further ana-
lysis was done among women above the age of 30 years
(n = 342) as the clinical and diagnostic relevance of
HPV infection is higher in women beyond the age of
30 (Table 3). In this sub-population we found no
significant difference in the age distribution across
the districts (P = 0.53). Multivariable analysis of HPV
prevalence in this age group showed still significantly
higher HPV prevalence in the eastern compared to
the western districts.
The peak age of overall HPV infection, multiple infec-
tions and infection with the commonest genotypes lies
between 21 and 25 years. This is followed by two lower
peaks at 36 to 40 years and at 50 to 55 years. Figure 2
shows the trends in HPV prevalence across age groups.
The overall trends in HPV prevalence peaks were
Table 2 Prevalence of HPV Infection by demographic and




Any HPV type HrHPVb
(n = 111) (n = 73)
OR (95 % CI) OR (95 % CI)
Age <30 years 1 1




Single/divorced 1.87 (1.17–2.99)*,e 1.16 (0.66–2.10)
Educational
status
Basic schooling 1 1
High school and
more
0.81 (0.53–1.25) 0.83 (0.50–1.37)
Districts Oberlandc 1 1
Unterlandd 1.76 (1.06–2.92)* 1.57 (0.88–2.79)
Smoking non-smoker 1 1
smoker 4.10 (2.6–6.41)* 3.16 (1.89–5.26)*
BMI <25 1 1
≥25 0.55 (0.32–0.95)* 0.64 (0.34–1.19)
Age at first
sexual contact
<16 years 1 1
≥16 years 0.44 (0.27–0.72)* 0.61 (0.35–1.08)
LSP <6 1 1
≥6 2.40 (1.39–3.62)* 1.95 (1.13–3.36)*
BMI body mass index, LSP number of life time sexual partners, OR odds ratio,
CI confidence interval
*p-value = statistically significant
aonly non-vaccinated women
bHPVs 16, 18, 31, 33, 45, 52 58 (all the HrHPV types included in nonavalen HPV vaccine)
cwestern districts (Imst, Landeck)
dEastern districts (Kufstein, Kitzbuehel)
esignificant for study participants above 30 years of age
Fig. 1 Distribution (%) of all detected HPV genotypes among screening population of women in west Austria
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statistically significant for overall HPV positivity (P = 0.001)
and for common high risk type infections (P = 0.035).
The compliance for HPV re-testing a year after the
initial test was low. A total of only 48 (47.1 %) women
initially positive for any hrHPV genotype were re-
tested 1 year after the baseline examination. Twenty
five (52.1 %) of the infections were persistent. No
statistically significant association was observed be-
tween HPV persistence and any of the sociodemo-
graphic factors.
Table 3 Multivariable adjusted prevalence of HPV Infection by demographic and behavioural characteristics among women above
and below 30 years of agea
Women ≥30 years Women < 30 years
Variables Variable categories Any HPV type HrHPVb Any HPV type HrHPVb
(n = 49) (n = 31) (n = 55) (n = 41)
OR (95 % CI) OR (95 % CI) OR (95 % CI)a OR (95 % CI)
Marital status Married/Partnershaft 1 1 1 1
Single/divorced 1.89 (0.87–4.14) 1.28 (0.49–3.32) 1.29 (0.58–2.85) 0.82 (0.35–1.93)
Educational status Basic schooling 1 1 1 1
High school and more 0.96 (0.47–1.97) 1.60 (0.67–3.82) 0.52 (0.24–1.17) 0.39 (0.17–0.94)*
Districts Oberlandc 1 1 1 1
Unterlandd 2.43 (1.06–5.60)* 2.66 (0.98–7.24)e 0.79 (0.32–1.96) 0.98 (0.38–2.50)
Smoking non-smoker 1 1 1 1
smoker 2.64 (1.30–5.37)* 2.09 (0.90–4.84) 3.34 (1.53–7.29)* 3.07 (1.33–7.09)*
BMI <25 1 1 1 1
≥25 0.39 (0.16–0.96)* 0.38 (0.13–1.17) 1.30 (0.51–3.30) 1.98 (0.84–4.67)
Age at first sexual contact <16 years 1 1 1 1
≥16 years 1.06 (0.37–3.00) 2.43 (0.51–11.5) 0.88 (0.40–1.94) 1.18 (0.50–2.77)
LSP <6 1 1 1 1
≥6 2.23 (1.06–4.68)* 2.11 (0.88–5.06) 0.86 (0.39–1.88) 0.98 (0.43–2.71)
BMI body mass index, LSP number of life time sexual partners
OR odds ratio, CI confidence interval, LSP lifetime sexual partner
*p-value = statistically significant
aanalysis using only non-vaccinated women, analysis adjusted for age, age at first sexual contact, LSP and smoking
bHPVs 16, 18, 31, 33, 45, 52 58 (all the HrHPV types included in nonavalen HPV vaccine)
cwestern districts (Imst, Landeck)
dEastern districts (Kufstein, Kitzbuehel)
eborderline significant
Fig. 2 Trends in age specific HPV prevalence among screening population of women in west Austria
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Cytology
Data on cytological examination were available for a total
of 384 women (Table 4). Twenty one (3.7 %) women were
diagnosed with PAPIII+, which were significantly associ-
ated with overall, high risk type and multiple HPV infec-
tion (P < 0.0001). Of the high-risk types, HPV 16 and 18
were significantly associated with adverse cytological out-
comes. Twenty four percent of HPV 16 positive women
have accompanying cytological findings of PAP III+. The
proportion of smokers is significantly higher among those
with PAP III+ [OR = 4.15 (95 % CI: 1.63–10.57)]. A total
of 48 high-risk positive patients were re-tested once
again 9–15 months after the baseline examination.
Twenty-three (52 %) women had persistent infection,
the majority of them being HPV 16. Persistent HPV in-
fection was higher among those with abnormal PAP
finding, however not statistically significant [OR = 1.56
(95 % CI: 0.41–5.84)].
Discussion
HPV prevalence
Prevalence of HPV DNA in a screening population of
women aged 18 to 65 years in west Austria was 20.5 %,
with the highest prevalence (33.9 %) seen among
women aged 21 to 25 years. Although the overall preva-
lence was slightly higher than the crude HPV preva-
lence worldwide, the pattern of age specific HPV
prevalence was shown to correspond to that seen in
other regions [19–21]. Slight differences may be due to
differences in the type of test used for the HPV detec-
tion or differences in the study population selected.
Slightly over 60 % of all the infections are detected
among women below 25 years of age, which may repre-
sent a high susceptibility of HPV infection right after
sexual debut. Like in studies from other region, our
study also showed other smaller peaks in higher age
groups [22]. There is no clear reason as to why HPV
prevalence peaks once again in a later age. One com-
monly accepted assumption is the fact that divorce and
separation tends to put many women back into new-
partner sexual relationships. Previous studies attribute
the increased prevalence of sexually transmitted infec-
tions among older women to an increased divorce rate
[23, 24]. Demographic data in Austria (Statistik Austria)
report that the peak age for divorce is around 35–40
years [24] which corresponds to our finding of a second
HPV peak at around this age range. The second HPV
re-peak between 51 and 55 years of age may likewise be
explained by an increased risk of new infections as well
as by the accompanying age-related anatomical changes in
the vulva and vaginal mucosa following menopause at this
age. Another explanation for the HPV surge in an older
age may be the hypothesis of a latent HPV infection per-
sisting below detection limit and reactivating at some
point due to declining immunity or other comorbidities
commonly seen in advanced age. This hypothesis has been
evidenced in some animal studies or in patients with re-
current respiratory papillomatosis [25–28].
As in several other studies, HPV 16 is clearly the most
dominant genotype. It is detected in cervical samples of
one out of 20 of the study population. Although HPV 18
is the second common genotype present in cervical cancer
samples, it is obviously surpassed by several other geno-
types among women with no known cytological abnor-
malities [29]. Genotypes 31 and 33 – for example - were
shown to dominate cervical infection following HPV 16
both in our study and in a study from several European
countries [29]. This pattern was also shown to persist
among women with high-grade intraepithelial neoplasia
[29]. Moreover, data from the WHO ICO information
centre on HPV infection (last updated on 20th March
2015) reports that HPV 33 may be the second common
genotype detected in cervical cancer samples next to HPV
16 in Austria [30]. The plausibility of this report, however,
is questionable. Moreover, in our study, only one of the
women with HPV 33 positive samples was diagnosed with
abnormal PAP. Further epidemiological studies need to be
undertaken in order to clarify or solidify this prevalence
pattern among cervical cancer patients in Austria.
HPV infection and lifestyle factors
Our study showed a threefold higher risk of HPV infec-
tion among current smokers, which persisted even after
Table 4 HPV prevalence and distribution of high risk and low
risk genotypes across cytological findings
PAP positive PAP negative
(PAP III+) (n = 21) (PAP I-II) (n = 363)
Age, years 32.6 (8.1) 35.9 (11.5)
Mean (SD)
Age at firts sexual contact, years 16.8 (2.8) 16.8 (2.4)
Mean (SD)
BMI, Mean (SD) 22.5 (3.3) 23.4 (4.0)
Current smoker, n (%) 14 (66.7) 117 (32.5)*
HPV positive, n (%) 19 (90.5) 75 (20.7)*
Multiple HPV infection, n (%) 7 (33.3) 33 (9.1)*
Nonavalent type HrHPV, n (%)a 15 (71.4) 48 (13.2)*
HPV 16, n (%) 9 (45) 20 (5.8)*
HPV 18, n (%) 2 (9.5) 4 (1.1)*
HPV 31, n (%) 1 (4.8) 13 (3.6)
HPV 33, n (%) 1 (4.8) 14 (3.9)
SD standard deviation, HrHPV high risk HPV genotypes
PAP III + abnormal PAPanicolaou (cervical smear cytology) including PAP III,
PAP IIID, PAP IVA and IVB and PAP V
PAPI-II normal PAPanicolaou (cervical smear cytology)
*P = sig
a16, 18, 31, 33, 45, 52 58 (all HrHPV types included in nonavalen HPV vaccine)
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adjusting for other behavioural factors like number of
lifetime sexual partners and age at first sexual contact.
This might indicate that smoking per se predisposes to
HPV infection as is also shown by other studies [31–33].
Tobacco use was reported to have local and systemic
immunosuppression effect increasing the probability of
acquisition of an HPV infection following an exposure
[33]. The exact biological mechanism, however, is not
yet clear. This highlights the need to evaluate the exact
role of smoking in the natural history of genital HPV in-
fection. Contrary to smoking, high BMI was not associ-
ated with increased risk of HPV infection. The fact that
HPV infection was significantly higher in non-overweight
individuals in our study might be a finding by chance or it
might indicate a possible association between physical ap-
pearance and sexual behaviour.
HPV infection across Tyrolean districts
Our finding of higher HPV prevalence in eastern dis-
tricts of Tyrol compared to those in the west seems to
parallel the regional differences in cervical cancer inci-
dence and mortality observed by W Oberaigner et al.
[16]. This association persisted even after eliminating
the significant age difference between the two regions.
Other confounding factors like number of life time sex-
ual partners and age at first sexual contact were consid-
ered and adjusted for. Yet the significant difference in
HPV prevalence between east and west was persistent,
particularly among women above the age of 30 years.
However, since questions regarding sexual behaviour
may be sensitive, responders’ bias and residual con-
founding due to these factors can still not be convin-
cingly excluded. Other host and /or pathogen associated
factors differentially predisposing to HPV infection and
persistence across these geographical regions may be in-
teresting to investigate.
HPV immunization
Surveys from several countries that have introduced
free-of-charge HPV vaccination program since the ap-
proval of the vaccines have demonstrated a high vaccine
coverage rate of more than 70 % [8, 34]. Accordingly,
the prevalence of hrHPV infection has reduced signifi-
cantly in the years after vaccine introduction. The low
immunization coverage (3.7 %) in the Austrian popula-
tion may be, on one hand, a reflection of the reluctance
of the country to provide the vaccine free of charge for
the eligible age group coupled with the conservative
view of the population towards vaccines particularly to-
wards newly introduced vaccines. On the other hand,
however, with the median age of 35 years, the majority of
our study population was beyond the age of eligibility as
the vaccines were introduced explaining the low coverage
to some extent. Our study assessed the attitudes of the
study population towards HPV vaccine. The fact that ma-
jority of the studied women showed undecidedness about
getting vaccinated- which may indirectly reflect undecid-
edness about letting their children vaccinated - indicates
the urgent demand for public health action towards rais-
ing awareness on HPV vaccine. Further surveys need to be
undertaken which investigate the level of information and
the possible barriers to HPV vaccine acceptance.
Conclusion
This study presents the first data on prevalence and
genotype distribution of cervical HPV infections among
women with no previously known cytological abnormal-
ities in west Austria. Factors including smoking, number
of life time sexual partners, age at first sexual contact
and several socio-demographic factors, namely marital
status and geographical region were identified as risk
factors for age adjusted HPV prevalence. The finding of
higher HPV prevalence in the eastern compared to the
western district of the study region may - at least partly
- explain the east–west gradient in the standardized inci-
dence rate of cervical cancer in the region. The strikingly
low HPV vaccine coverage may change with the recently
introduced school-based vaccination program [35]. On
the other hand, this data – with the extremely low vac-
cine coverage rate – will serve as baseline pre-vaccine
information for further evaluation of the impact of the
newly implemented gender-neutral HPV vaccine pro-
gram in Austria.
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